Abeona Therapeutics Inc.
https://www.abeonatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abeona Therapeutics Inc.
US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics
Five novel agents are among the user fee goal dates coming up in May 2024.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Finance Watch: Kyverna, Alto Offerings Could Land In IPO Investors’ Sweet Spot
Public Company Edition: Kyverna and Alto Neuroscience, which may go public in the US this year, have drug candidates in or nearing mid-stage trials. Also, Zealand’s private placement raises $211.4m, Praxis prices a $150m offering and Solid grosses $108.9m in stock sale.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Access Pharmaceuticals, Inc.
- PlasmaTech Biopharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice